Publication: BIOTECH Patent News
Publication Date: 01-SEP-07
Delivery: Immediate Online Access
Author:
Company: Xenomics Inc.
Article Excerpt
Xenomics, Inc. (New York, NY) has granted Asuragen, Inc. co-exclusive worldwide rights to incorporate NPM1 technology into Asuragen's molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML).
AML is a clinically heterogeneous disease with an estimated 13,500 new cases per year in the United States and 200,000 worldwide. The disease subgrouping by karyotypic abnormalities indicates patient prognosis. However, in almost half of AML cases the karyotype appears normal and...
NOTE: All illustrations and photos have been removed from this article.
More articles from
BIOTECH Patent News
Ajinomoto obtains United States patent., 01-SEP-07
University of Wyoming obtains United States patent., 01-SEP-07
Celtrix obtains United States patent., 01-SEP-07
Looking for additional articles?
Click here to search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Click here to search our complete database of Industry & Market reports by text, subject, publication name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.
Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information. |
